Status:

UNKNOWN

Cardiovascular Consequences of NIV Withdrawal in Patients With Myotonic Dystrophy

Lead Sponsor:

University Hospital, Grenoble

Conditions:

Myotonia

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Background: Myotonic dystrophy lead to highly heterogeneous, multisystemic symptoms including myotonia, progressive muscle weakness, cardiac conduction defects, cataract, metabolic dysfunction, and ex...

Detailed Description

NIV is a technique of assisted ventilation that does not use the endotracheal route as the interface between the patient and the ventilator. NIV by positive pressure assistance involves ventilating th...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Patients (\>18 yrs) suffering from myotonic dystrophy already treated by long term nocturnal non invasive ventilation for more than six months for a chronic hypercapnic respiratory failure (Level of PaCO2 at beginning of the treatment should be between 45 and 55 mmHg)
  • Patients should use his (her) non-invasive ventilation more than 4 hours and less than 12 hours per day.
  • Patients could have an associated obstructive or/and central sleep apnea.
  • NIV treatment should be consider as "efficient ": To allow an improvement of PaCO2 during wakefulness in the morning when using NIV compared to PaCO2 at the beginning of the treatment; To allow an improvement of the nocturnal oxymetry compared to baseline (mean nocturnal SaO2 \> 90%).
  • EXCLUSION CRITERIA:
  • Patients with a concomitant respiratory condition contributing to daytime alveolar hypoventilation.
  • Patients judged by investigators as at high cardiovascular risk, this contraindicating NIV withdrawal.
  • Patients with cardiac failure and periodic breathing.
  • Patients who have had an acute episode of respiratory failure in the previous month.
  • Incapacitated patients in accordance with article L 1121-6 of the public health code.
  • Patients treated by oral corticosteroids or oral long-term non-steroidal anti-inflammatory drugs (NSAID).

Exclusion

    Key Trial Info

    Start Date :

    June 1 2008

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2012

    Estimated Enrollment :

    35 Patients enrolled

    Trial Details

    Trial ID

    NCT00745238

    Start Date

    June 1 2008

    End Date

    December 1 2012

    Last Update

    August 13 2012

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    France.Functional Cardio-Respiratory Exploration Laboratory

    Grenoble, Isere, France, 38000

    Cardiovascular Consequences of NIV Withdrawal in Patients With Myotonic Dystrophy | DecenTrialz